Abstract
Treatment-related late toxicities after pediatric allogeneic hematopoietic SCT (allo-HSCT) are increasingly important as long-term survival has become an expected outcome for many transplanted children and adolescents. In a retrospective cohort study, we assessed long-term health outcomes in 204 allo-HSCT survivors transplanted in childhood or adolescence (<20 years) between 1978 through 2000 after a median follow-up time of 12 (range 4–28) years. Data on conditioning regimen, adverse health events (AE) and growth and hormonal substitutions (hormone replacement therapies (HRTs)) were obtained from medical records. AEs were graded retrospectively according to Common Terminology Criteria for Adverse Events v3.0. Late deaths (⩾48 months after allo-HSCT) were evaluated separately. Multivariate analysis demonstrated that chronic GVHD (P<0.000) and longer follow-up time (P<0.05) correlated with AEs, whereas CY-based conditioning was inversely correlated (P<0.002). TBI and longer follow-up duration predicted more severe AEs (P<0.001 and P<0.001, respectively). HRTs were more frequent after TBI. Diabetes type II, dyslipidemia and hypertension were detected in 9, 7 and 7% of the survivors, respectively. Late deaths (n=22) were most frequently due to pulmonary failure (n=7), followed by secondary malignancy (n=5). The occurrence of AEs after pediatric allo-HSCT is high and likely to increase during extended follow-up, particularly in patients who have received TBI.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Miano M, Labopin M, Hartmann O, Angelucci E, Cornish J, Gluckman E et al. Haematopoietic stem cell transplantation trends in children over the last three decades: a survey by the paediatric diseases working party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2007; 39: 89–99.
Leiper AD . Non-endocrine late complications of bone marrow transplantation in childhood: part II. Br J Haematol 2002; 118: 23–43.
Socie G, Salooja N, Cohen A, Rovelli A, Carreras E, Locasciulli A et al. Nonmalignant late effects after allogeneic stem cell transplantation. Blood 2003; 101: 3373–3385.
Faraci M, Bekassy AN, De Fazio V, Tichelli A, Dini G . Non-endocrine late complications in children after allogeneic haematopoietic SCT. Bone Marrow Transplant 2008; 41: S49–S57.
Leiper AD . Non-endocrine late complications of bone marrow transplantation in childhood: part I. Br J Haematol 2002; 118: 3–22.
Ferry C, Gemayel G, Rocha V, Labopin M, Esperou H, Robin M et al. Long-term outcomes after allogeneic stem cell transplantation for children with hematological malignancies. Bone Marrow Transplant 2007; 40: 219–224.
Cohen A, Bekassy AN, Gaiero A, Faraci M, Zecca S, Tichelli A et al. Endocrinological late complications after hematopoietic SCT in children. Bone Marrow Transplant 2008; 41: S43–S48.
Mulcahy Levy JM, Tello T, Giller R, Wilkening G, Quinones R, Keating AK et al. Late effects of total body irradiation and hematopoietic stem cell transplant in children under 3 years of age. Pediatr Blood Cancer 2013; 60: 700–704.
Kunkele A, Engelhard M, Hauffa BP, Mellies U, Muntjes C, Huer C et al. Long-term follow-up of pediatric patients receiving total body irradiation before hematopoietic stem cell transplantation and post-transplant survival of>2 years. Pediatr Blood Cancer 2013; 60: 1792–1797.
Bresters D, van Gils IC, Kollen WJ, Ball LM, Oostdijk W, van der Bom JG et al. High burden of late effects after haematopoietic stem cell transplantation in childhood: a single-centre study. Bone Marrow Transplant 2010; 45: 79–85.
Lie SO, Abrahamsson J, Clausen N, Forestier E, Hasle H, Hovi L et al. Long-term results in children with AML: NOPHO-AML Study Group—report of three consecutive trials. Leukemia 2005; 19: 2090–2100.
Gustafsson G, Schmiegelow K, Forestier E, Clausen N, Glomstein A, Jonmundsson G et al. Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO). Leukemia 2000; 14: 2267–2275.
Wikland KA, Luo ZC, Niklasson A, Karlberg J . Swedish population-based longitudinal reference values from birth to 18 years of age for height, weight and head circumference. Acta Paediatr 2002; 91: 739–754.
Armenian SH, Sun CL, Kawashima T, Arora M, Leisenring W, Sklar CA et al. Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS). Blood 2011; 118: 1413–1420.
Sanders JE, Woolfrey AE, Carpenter PA, Storer BE, Hoffmeister PA, Deeg HJ et al. Late effects among pediatric patients followed for nearly 4 decades after transplantation for severe aplastic anemia. Blood 2011; 118: 1421–1428.
Schechter T, Gassas A, Chen H, Pollard J, Meshinchi S, Zaidman I et al. The outcome of allogeneic hematopoietic cell transplantation for children with FMS-like tyrosine kinase 3 internal tandem duplication–positive acute myelogenous leukemia. Biol Blood Marrow Transplant 2015; 21: 172–175.
Litzow MR, Perez WS, Klein JP, Bolwell BJ, Camitta B, Copelan EA et al. Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission. Br J Haematol 2002; 119: 1115–1124.
Davies SM, Ramsay NK, Klein JP, Weisdorf DJ, Bolwell B, Cahn JY et al. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol 2000; 18: 340–347.
Bunin N, Aplenc R, Kamani N, Shaw K, Cnaan A, Simms S . Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study. Bone Marrow Transplant 2003; 32: 543–548.
Wilhelmsson M, Vatanen A, Borgström B, Gustafsson B, Taskinen M, Saarinen-Pihkala UM et al. Adult testicular volume predicts spermatogenetic recovery after allogeneic HSCT in childhood and adolescence. Pediatr Blood Cancer 2014; 61: 1094–1100.
Bernard F, Auquier P, Herrmann I, Contet A, Poiree M, Demeocq F et al. Health status of childhood leukemia survivors who received hematopoietic cell transplantation after BU or TBI: an LEA study. Bone Marrow Transplant 2014; 49: 709–716.
Ferry C, Socié G . Busulfan-cyclophosphamide versus total body irradiation–cyclophosphamide as preparative regimen before allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia: What have we learned? Exp Hematol 2003; 31: 1182–1186.
Rovo A, Tichelli A . Cardiovascular complications in long-term survivors after allogeneic hematopoietic stem cell transplantation. Semin Hematol 2012; 49: 25–34.
Elhasid R, Leshem YA, Ben Arush MW, Rowe JM, Shehadeh N . Insulin-related metabolism following hematopoietic stem cell transplantation in childhood. Pediatr Diabetes 2009; 10: 149–154.
Annaloro C, Airaghi L, Saporiti G, Onida F, Cortelezzi A, Deliliers GL . Metabolic syndrome in patients with hematological diseases. Expert Rev Hematol 2012; 5: 439–458.
Taskinen M, Saarinen-Pihkala UM, Hovi L, Lipsanen-Nyman M . Impaired glucose tolerance and dyslipidaemia as late effects after bone-marrow transplantation in childhood. Lancet 2000; 356: 993–997.
Chow EJ, Baker KS, Lee SJ, Flowers ME, Cushing-Haugen KL, Inamoto Y et al. Influence of conventional cardiovascular risk factors and lifestyle characteristics on cardiovascular disease after hematopoietic cell transplantation. J Clin Oncol 2014; 32: 191–198.
Norberg M, Danielsson M . Overweight, cardiovascular diseases and diabetes: health in Sweden: The National Public Health Report 2012. Chapter 7. Scand J Public Health 2012; 40: 135–163.
Holmqvist AS, Olsen JH, Andersen KK, de Fine Licht S, Hjorth L, Garwicz S et al. Adult life after childhood cancer in Scandinavia: diabetes mellitus following treatment for cancer in childhood. Eur J Cancer 2014; 50: 1169–1175.
Oudin C, Simeoni MC, Sirvent N, Contet A, Begu-Le Coroller A, Bordigoni P et al. Prevalence and risk factors of the metabolic syndrome in adult survivors of childhood leukemia. Blood 2011; 117: 4442–4448.
Bajwa R, Skeens M, Garee A, Miao Y, Soni S, Pietryga D et al. Metabolic syndrome and endocrine dysfunctions after HSCT in children. Pediatr Transplant 2012; 16: 872–878.
Guldner L, Haddy N, Pein F, Diallo I, Shamsaldin A, Dahan M et al. Radiation dose and long term risk of cardiac pathology following radiotherapy and anthracyclin for a childhood cancer. Radiother Oncol 2006; 81: 47–56.
Kero AE, Jarvela LS, Arola M, Malila N, Madanat-Harjuoja LM, Matomaki J et al. Cardiovascular morbidity in long-term survivors of early-onset cancer: a population-based study. Int J Cancer 2014; 134: 664–673.
Armstrong GT, Kawashima T, Leisenring W, Stratton K, Stovall M, Hudson MM et al. Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study. J Clin Oncol 2014; 32: 1218–1227.
Socie G, Baker KS, Bhatia S . Subsequent malignant neoplasms after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012; 18: S139–S150.
Schechter T, Pole JD, Darmawikarta D, Doyle J, Ali M, Egeler M et al. Late mortality after hematopoietic SCT for a childhood malignancy. Bone Marrow Transplant 2013; 48: 1291–1295.
Bhatia S, Francisco L, Carter A, Sun CL, Baker KS, Gurney JG et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood 2007; 110: 3784–3792.
Williams KM, Chien JW, Gladwin MT, Pavletic SZ . Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. JAMA 2009; 302: 306–314.
Smedler AC, Winiarski J . Neuropsychological outcome in very young hematopoietic SCT recipients in relation to pretransplant conditioning. Bone Marrow Transplant 2008; 42: 515–522.
Acknowledgements
We thank Björn Jonsson for help with statistical analysis and Jaana Vettenranta, Satu Ranta, Pirjo Valtonen and Otto Wilhelmsson for skillful technical assistance. This study was supported by grants from the Swedish Childhood Cancer Foundation, Stockholm City Council, the Finnish Cancer Society, the Finnish Pediatric Research Foundation, Paulo Foundation, the Nona and Kullervo Väre Foundation and the Academy of Finland.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Wilhelmsson, M., Vatanen, A., Borgström, B. et al. Adverse health events and late mortality after pediatric allogeneic hematopoietic SCT—two decades of longitudinal follow-up. Bone Marrow Transplant 50, 850–857 (2015). https://doi.org/10.1038/bmt.2015.43
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2015.43
This article is cited by
-
Impact of lung function impairment after allogeneic hematopoietic stem cell transplantation
Scientific Reports (2022)
-
Anxiety, depression, and mental health-related quality of life in survivors of pediatric allogeneic hematopoietic stem cell transplantation: a systematic review
Bone Marrow Transplantation (2020)
-
Long-term health outcomes in survivors of childhood AML treated with allogeneic HSCT: a NOPHO–AML Study
Bone Marrow Transplantation (2019)
-
Late mortality after allogeneic blood or marrow transplantation in childhood for leukemia: a report from the Blood or Marrow Transplant Survivor Study-2
Leukemia (2018)
-
Skeletal outcome in long-term survivors of childhood high-risk neuroblastoma treated with high-dose therapy and autologous stem cell rescue
Bone Marrow Transplantation (2017)